These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18589484)

  • 1. Update on antiretroviral therapy: the 15th CROI.
    Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax P
    AIDS Read; 2008 May; 18(5):273-8, C3. PubMed ID: 18589484
    [No Abstract]   [Full Text] [Related]  

  • 2. New antiretroviral drugs in development.
    Murphy RL
    AIDS; 2000; 14 Suppl 3():S227-34. PubMed ID: 11086866
    [No Abstract]   [Full Text] [Related]  

  • 3. [Nucleoside reverse transcriptase inhibitors. Sex-specific effectiveness and tolerance].
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():42-3. PubMed ID: 10863310
    [No Abstract]   [Full Text] [Related]  

  • 4. [New fixed once daily combination as nucleoside backbone. Basis for long-term therapy success].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():66-8. PubMed ID: 16385881
    [No Abstract]   [Full Text] [Related]  

  • 5. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory issues in the era of highly active antiretroviral therapy.
    Murray JS
    AIDS; 2000; 14 Suppl 3():S219-25. PubMed ID: 11086865
    [No Abstract]   [Full Text] [Related]  

  • 7. Nucleoside analogues in 2008.
    Warwick Z; Churchill D
    J HIV Ther; 2008 Mar; 13(1):3-8. PubMed ID: 18953267
    [No Abstract]   [Full Text] [Related]  

  • 8. Update from CROI 2008 on HIV-related infections and conditions.
    McCord A
    Proj Inf Perspect; 2008 Apr; (45):17-24. PubMed ID: 19248294
    [No Abstract]   [Full Text] [Related]  

  • 9. Key clinical trials of non-nucleoside reverse transcriptase inhibitors in the treatment of chronic HIV-1 infection in adults.
    Williams I
    J HIV Ther; 2008 Mar; 13(1):19-23. PubMed ID: 18953269
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiretrovirals in the pipeline: anticipated updates.
    Laurence J
    AIDS Read; 2005 Nov; 15(11):577-8. PubMed ID: 16329178
    [No Abstract]   [Full Text] [Related]  

  • 11. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 12. First-line antiretroviral therapy in resource-limited settings: time to reconsider?
    Adlington R; Richens J; Shahmanesh M
    J Infect Dis; 2009 May; 199(9):1407; author reply 1407-8. PubMed ID: 19358673
    [No Abstract]   [Full Text] [Related]  

  • 13. Stavudine in antiretroviral therapy: is this the end?
    Brinkman K
    AIDS; 2009 Aug; 23(13):1727-9. PubMed ID: 19571724
    [No Abstract]   [Full Text] [Related]  

  • 14. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008).
    Pujari S; Patel A; Joshi SR; Gangakhedkar R; Kumarasamy N; Gupta SB;
    J Assoc Physicians India; 2008 May; 56():339-48, 353-71. PubMed ID: 18700643
    [No Abstract]   [Full Text] [Related]  

  • 16. Update from CROI 2008 on approved HIV drugs.
    Dalton P
    Proj Inf Perspect; 2008 Apr; (45):9-17. PubMed ID: 19248293
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiretroviral therapy roundup from CROI. Report on newer drugs in development and some already approved drugs.
    Berry J
    Posit Aware; 2008; 19(3):20-3. PubMed ID: 18724440
    [No Abstract]   [Full Text] [Related]  

  • 18. Top stories of 2008. Antiretroviral rollout--successes and challenges.
    Friedland GH
    AIDS Clin Care; 2009 Jan; 21(1):5. PubMed ID: 19219959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current HIV therapeutics: mechanistic and chemical determinants of toxicity.
    Chiao SK; Romero DL; Johnson DE
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):53-60. PubMed ID: 19152213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.